Brief: Creative Medical Technology Holdings Inc Announced Positive Three-Year Follow-Up Data For Company's Stemspine Pilot Study
14/02/2023 13:21
Feb 14 (Reuters) - Creative Medical Technology Holdings
Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC - ANNOUNCED
POSITIVE
THREE-YEAR FOLLOW-UP DATA FOR COMPANY'S STEMSPINE® PILOT STUDY
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC - THERE WERE NO
SAFETY
RELATED CONCERNS AT UP TO THREE YEARS
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS- STEMSPINE® PROCEDURE
RESULTED IN A CONTINUED EFFICACY RATE OF 87% OF PATIENTS THAT
PARTICIPATED IN PILOT STUDY
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC - NO PATIENTS
REQUIRED
RE-DOSAGE OR SURGICAL INTERVENTION SINCE LAST FOLLOW-UP AT TWO
YEARS
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS - THREE-YEAR DATA
DEMONSTRATES CONTINUED EFFICACY OF STEMSPINE® PROCEDURE FOR
TREATING CHRONIC LOWER BACK PAIN
Source text for Eikon: ID:nBw8LqYcBa
Further company coverage: CELZ.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM